Methotrexat als Therapiestrategie bei chronisch entzündlichen Darmerkrankungen

  title={Methotrexat als Therapiestrategie bei chronisch entz{\"u}ndlichen Darmerkrankungen},
  author={M. G{\"o}ke},
Die Behandlung der Patienten mit chronisch entziindlichen Darmerkrankungen (CED),die einen steroidabhangigen oder steroidrefraktaren chronisch aktiven Verlauf zeigen, stellen den behandelnden Arzt sowohl hin-sichtlich der Induktion einer Remission als auch hinsichtlich des Remis-sionserhaltes vor anspruchsvolle Therapieentscheidungen. In den letzten Jahren mehren sich therapeutische Angebote, wobei sich der in der Tumortherapie bekannte Antimetabolit Methotrexat (MTX) in einer im Vergleich zu… Expand


Methotrexate for refractory Crohn's disease: preliminary answers to definitive questions.
Encyclopedic in scope , the article in this issue of the Mayo Clinic Proceedings (pages 69 to 80) by Egan and Sandborn reviews the pharmacologic propert ies of methotrexate, its potential in theExpand
[Methotrexate in therapy of gastrointestinal diseases].
This review is not only a comprehensive synopsis of the published data on methotrexate treatment for inflammatory bowel disease and primary biliary cirrhosis but gives also an overview about actingExpand
Methotrexate for inflammatory bowel disease: pharmacology and preliminary results.
Methotrexate is a promising new agent for the treatment of inflammatory bowel disease and is generally well tolerated for long-term use at a low dose, several serious toxicities potentially limit its use. Expand
Liver biopsies from psoriatics related to methotrexate therapy. 2. Findings before and after methotexate therapy in 88 patients. A blind study.
  • A. Nyfors, H. Poulsen
  • Medicine
  • Acta pathologica et microbiologica Scandinavica. Section A, Pathology
  • 1976
For use ofMTX therapy in psoriasis the following precautions are suggested: MTX therapy should be used only in disabling cases; a pre-MTX liver biopsy and repeat liver biopsies at regular intervals of 1/2-1 year should be performed, alcohol should be prohibited and frequent inquiries should be made about the patient's alcoholic intake. Expand
Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis: A Double-Blind, Placebo-Controlled Trial
A larger and longer study to evaluate different doses of folic acid, assuming that toxicity could be reduced without changing the efficacy of methotrexate, and the influence of the folic Acid dose on metotrexate toxicity and efficacy remains controversial. Expand
Methotrexate-related pulmonary complications in rheumatoid arthritis.
Methotrexate was approved by the food and drug administration for the treatment of severe and disabling psoriasis in 1971 and for RA only in 1988 and pulmonary toxicity was first observed during treatment of childhood leukaemia in 1969 and later in malignancies, Psoriasis and polymyositis. Expand
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
Infliximab was well-tolerated; withdrawals for adverse events as well as the occurrence of serious adverse events or serious infections did not exceed those in the placebo group. Expand
Methotrexate in rheumatoid arthritis.
The recommendations for monitoring and selection of patients for liver biopsy identify patients at potential risk for CSLD, and thus significantly reduce the number or patients who would be exposed to this procedure. Expand
Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.
A pilot study to determine whether methotrexate has anti-inflammatory activity in refractory inflammatory bowel disease found that 16 of twenty-one patients had an objective response as measured by disease activity indices, and further work is needed before the drug can be recommended forinflammatory bowel disease. Expand
Methotrexate induced liver cirrhosis
Factors contributing to cirrhosis in this study seem to be previous treatment with arsenic, a previous intake of alcohol, and lowered renal function. Expand